On October 25, 2021 Exact Sciences Corp. (NASDAQ: EXAS) reported that data from modeling analyses that demonstrate Cologuard (mt-sDNA), with its included patient navigation system, provides a greater reduction in incidence and mortality from colorectal cancer (CRC) compared to annual fecal immunochemical test (FIT), when it included outreach, with or without a mailed annual FIT, using real world adherence rates in a simulated Medicaid population (Press release, Exact Sciences, OCT 25, 2021, View Source [SID1234591899]). Cologuard remained cost-effective in all the real-world adherence scenarios modeled. The modeling analyses were consistent with the CISNET Colorectal Working Group models when using 100% adherence rates.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cologuard Data Models Impact on CRC Incidence, Mortality and Cost Effectiveness in a Medicaid Population
The Exact Sciences Laboratories Patient Navigation Program features on-demand phone support, reminder phone calls, texts and emails at no additional cost with each Cologuard test ordered.
These new data, generated from the CRC-AIM microsimulation model, will be presented in an ACG Presidential Award-winning poster titled, "Cost-Effectiveness of Stool-Based Colorectal Cancer Screening Using Reported Real-World Adherence Rates in a Medicare Population." (P1181)
"Colorectal cancer screening rates need improvement, and they are particularly low in vulnerable populations,"1 said Paul Limburg, M.D., Chief Medical Officer, Screening at Exact Sciences. "Exact Sciences Laboratories’ patient navigation program answers any question around sample collection and offers phone and text reminders to complete the testing process. It is a way to help all patients, including vulnerable patients, prioritize their health and get up to date with CRC screening."
Colorectal cancer is the second deadliest cancer impacting both men and women in the U.S. Earlier detection of colorectal cancer through effective screening has been shown to improve clinical outcomes.2,3
All abstracts and posters presented at the meeting can be accessed through this link. Additional Cologuard abstracts accepted for presentation include:
Adherence to colorectal cancer screening and associated healthcare resource utilization, a longitudinal analysis in US Medicare population with ten years follow-up (PO246)
Colorectal cancer screening rates and associated characteristics among US Medicare beneficiaries aged 66-75 years old in 2016-2018 (PO245)
Impact of mt- sDNA in a colorectal cancer screening clinical practice: a real-world survey (PO247)
Multitarget stool DNA testing has a high positive predictive value for colorectal neoplasia on the second round of testing (P1318)
Initial colorectal cancer screenings after turning 50-year-old and follow-up screening patterns after positive FIT or multitarget stool DNA testing among average-risk population (P1330)
Colorectal cancer screening and adherence rates among average-risk population enrolled in a national health insurance provider during 2009-2018 (P2345)